Strides Pharma Science reported a consolidated profit after tax (PAT) of ₹1,655 million for Q1FY27, marking a 56.7% year-on-year increase. The bottom-line expansion was primarily driven by a one-time exceptional gain of ₹742.07 million from the dilution of its controlling stake in Pivot Path Private Limited, which contributed ₹534 million to PAT net of tax. Excluding this non-recurring item, operational PAT rose 8% to ₹1,231 million, demonstrating underlying resilience despite absorbing approximately ₹131 million in elevated freight and operating costs linked to geopolitical disruptions in the Middle East.

The unaudited financial results for the quarter ended June 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors on July 31, 2026. The Statutory Auditors carried out a limited review of the standalone and consolidated financial results, prepared in accordance with Ind AS. Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published newspaper advertisements in 'Financial Express' and 'Lokmat' on August 1, 2026, providing an extract of the unaudited financial results. The full format of the quarterly financial results has been filed with the stock exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015.

Consolidated revenue from operations grew 13% year-on-year to ₹12,654 million. The growth was broad-based, with Ex-US markets delivering a robust 17% expansion to ₹5,875 million ($63 million), while the US business remained steady at ₹6,282 million ($68 million). Badree Komandur, Managing Director and Group CEO, attributed the performance to successful diversification strategies and strong execution in regulated markets across Europe, the UK, Nordics, and Africa.

Financial Performance Highlights

Gross margin expanded by 14% year-on-year to ₹7,702 million, improving the gross margin percentage by 60 basis points to 60.9%. This improvement was driven by a favorable business mix within Ex-US markets. However, EBITDA margin contracted slightly to 18.2% from 19.5% in Q1FY26, as absolute operating costs outpaced revenue growth. Vikesh Kumar, Group CFO, noted that employee costs held steady at 19.2% of revenue, while other operating costs increased by ₹29.0 million due to higher manufacturing expenses. Freight costs rose to 6.2% of revenue from 5.3% a year ago, an increase of ₹18.9 million.

The company reduced net debt by ₹119 million during the quarter, bringing closing net debt to ₹1,424.6 million and the Net Debt-to-EBITDA ratio to 1.52x. Operating cash flow stood at ₹1,087 million for the quarter, representing an EBITDA-to-cash conversion of 47%. CARE Ratings upgraded the company's Long-Term Bank Facilities rating to CARE A+; Stable from CARE A; Positive, reflecting improved creditworthiness.

Strategic Developments and Market Outlook

In the US market, Strides Pharma Science launched two new products in Q1FY27, bringing the total number of commercialized products to 72. The company continues to rank among the top three in 37 products, contributing approximately 70% of total US revenue. Management expects new product approvals in H2FY27 and aims for North America business revenue of ~$375 million by FY28. A key growth lever is the Controlled Substances portfolio, where quota allocations are expected to improve after demonstrating past sales history over 1.5 years. The company also filed a second Nasal Spray product in May 2026 and expects approval for the first nasal spray filing in H2FY27.

Ex-US markets contributed significantly to growth, with strong customer advocacy enabling expansion in the UK and Nordics. Africa operations delivered stellar growth through the Brands business. While Ex-US revenue was lower sequentially compared to Q4FY26 due to temporary supply chain disruptions and shipment delays, management views this as a timing issue rather than a demand issue, expecting recovery in subsequent quarters.

What the Numbers Show

The divergence between 13% revenue growth and 5.40% EBITDA growth highlights the impact of macroeconomic pressures on operating efficiency. While gross margins expanded, indicating better product mix or pricing power, the compression in EBITDA margins suggests that selling, general, and administrative expenses or direct operational costs are rising faster than revenue. The strong 17% growth in Ex-US markets serves as a critical counterbalance to the steady US business, validating the company's diversification strategy. The reduction in net debt alongside healthy operational cash flows demonstrates prudent balance sheet management, positioning the company to withstand further geopolitical volatility. Additionally, the EcoVadis sustainability score improved to 68/100, a 19-point increase over the previous year.

Strides Pharma Science Limited has released the audio recording of its earnings call discussing the unaudited financial results for the quarter ended June 30, 2026. The call took place on Friday, July 31, 2026, at 17:00 hrs IST, providing investors and analysts with management commentary on the company's latest performance metrics. This disclosure ensures transparency and accessibility for stakeholders reviewing the Q4FY26 outcomes.

The release was made pursuant to Regulations 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These regulations mandate timely dissemination of material information to listed entities' shareholders and the broader market. By hosting the audio on its official website, Strides Pharma Science Limited complies with regulatory requirements for investor communication.

Earnings Call Details

The earnings call was conducted by Strides Pharma Science Limited to review its financial standing for the most recent quarter. The session allowed for direct interaction between company leadership and market participants, addressing queries related to operational performance and strategic initiatives.

Regulatory Compliance

Manjula Ramamurthy, Company Secretary & Compliance Officer at Strides Pharma Science Limited, signed off on the disclosure. Her ICSI Membership No. A30515 is cited in the official communication submitted to both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE). The notice was directed to the respective exchange offices in Mumbai.

The audio recording is accessible via the company’s investor relations portal. Stakeholders are advised to refer to the specific URL provided in the original filing for immediate access to the recording. This mechanism supports efficient information flow without requiring physical attendance or additional distribution channels.